Summer Sale
50% off Premium Yearly
NYSE:GSK
GlaxoSmithKline PLC (GSK)
Financials 
Technical Analysis 
Aug 25, 2026, 12:00 amThis summary was created by AI, based on 4 opinions in the last 12 months.
GlaxoSmithKline PLC (GSK-N) is being highlighted as a strong investment opportunity by multiple experts, especially in the currently volatile healthcare sector. With a recent earnings growth rate of 7%, this company demonstrates solid performance metrics and trades at an attractive valuation of 11 times earnings and 5.6 times book value, bolstered by a notable 43% return on equity (ROE). Analysts are recommending strategic stop-loss adjustments to protect profits, indicating confidence in a potential upside, with target prices ranging from $54.31 to $62. The stock also offers a yield of 3.3%, making it appealing for income-focused investors. Overall, the sentiment around GSK is overwhelmingly positive, as it is viewed as a reliable player in its sector amid prevailing market uncertainties.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPremium contentPremium content
Premium contentPremium contentPremium contentPremium contentWe reiterate GSK as a TOP PICK. We like that cash reserves are holding steady, despite an aggressive retirement of debt. It trades at 22x earnings and supports a 18% ROE. The solid dividend is backed by a payout ratio under 50% of cash flow. The company is partnering with another pharma to develop Parkinson's disease treatments. We continue to recommend a stop at $27, looking to achieve $41 -- upside potential over 20%. Yield 4.6%
(Analysts’ price target is $40.89)Premium contentThis large global biopharma company has reported continued success in a oncology based treatment for a blood cancer effecting 180,000 new patients annually. The company is building cash reserves while debt is retired. It trades at 22x earnings and supports a 21% ROE. We recommend setting a stop-loss at $27, looking to achieve $45 -- upside potential of 26%. Yield 4.5%
(Analysts’ price target is $45.07)
They sold their personal care business to generate a lot of capital. They're strong in vaccines, but don't have a strong pipeline of drugs. So, they need to buy other companies to make up for that. Not a high PE and pays a good dividend. The key is what they will do with their capital.
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Popular Articles
GlaxoSmithKline PLC (GSK) Frequently Asked Questions
What is GlaxoSmithKline PLC stock symbol?
GlaxoSmithKline PLC is a American stock, trading under the symbol GSK (previously GSK-N on Stockchase) on the New York Stock Exchange (GSK). It is usually referred to as NYSE:GSK or GSK
Is GlaxoSmithKline PLC a buy or a sell?
In the last year, 4 stock analysts issued a Buy, Sell, or Hold rating on GSK (previously GSK-N on Stockchase). 4 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for GlaxoSmithKline PLC.
Is GlaxoSmithKline PLC a good investment or a top pick?
GlaxoSmithKline PLC was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-07-30. Read the latest stock experts ratings for GlaxoSmithKline PLC.
Why is GlaxoSmithKline PLC stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for GlaxoSmithKline PLC.
Is GlaxoSmithKline PLC worth watching?
GlaxoSmithKline PLC is followed by 82 investors on Stockchase and is a trending stock that is worth watching.
What is GlaxoSmithKline PLC stock price?
On 2026-08-25, GlaxoSmithKline PLC (GSK) stock closed at a price of $52.07.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
We reiterate this global pharma company, as a TOP PICK. The healthcare sector has been a steady performer with recent market volatility and GSK is a key player in the space. Recent earnings growth was reported at 7%. It trades at 11x earnings, 5.6x book and supports a robust 43% ROE. We continue to recommend a stop at $50, looking to achieve $62 -- upside potential of 18%. Yield 3.3%
(Analysts’ price target is $54.31)